Trials / Recruiting
RecruitingNCT06280105
A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
A Single-arm, Multicenter, Phase II Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Progressed on Camrelizumab Combined With Apatinib
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Meng Chao Hepatobiliary Hospital of Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of cadonilimab combined with Regorafenib in patients with hepatocellular carcinoma who failed camrelizumab plus apatinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cadonilimab+regorafenib | cadonilimab: 6mg/kg iv D1 Q2W; regorafenib: 80mg QD oral; Eligible patients will receive cadonilimab combined with regorafenib, until disease progression or intolerable toxicity or death or withdrawal of informed consent, whichever occurred first |
Timeline
- Start date
- 2024-03-31
- Primary completion
- 2026-03-31
- Completion
- 2027-03-31
- First posted
- 2024-02-28
- Last updated
- 2025-05-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06280105. Inclusion in this directory is not an endorsement.